WO2005087794A1 - Process for octreotide synthesis - Google Patents

Process for octreotide synthesis Download PDF

Info

Publication number
WO2005087794A1
WO2005087794A1 PCT/CA2005/000378 CA2005000378W WO2005087794A1 WO 2005087794 A1 WO2005087794 A1 WO 2005087794A1 CA 2005000378 W CA2005000378 W CA 2005000378W WO 2005087794 A1 WO2005087794 A1 WO 2005087794A1
Authority
WO
WIPO (PCT)
Prior art keywords
boc
phe
cys
trt
thr
Prior art date
Application number
PCT/CA2005/000378
Other languages
French (fr)
Inventor
Alexei Iarov
Ilya Avrutov
Natalie Lazarowych
Stephen Houldsworth
Original Assignee
Dalton Chemical Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalton Chemical Laboratories Inc. filed Critical Dalton Chemical Laboratories Inc.
Publication of WO2005087794A1 publication Critical patent/WO2005087794A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • Octreotide is the active pharmaceutical ingredient of the drug Sandostatin, using in treatment of some cancer diseases, especially acromegaly etc. It has the following chemical structure: (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol.
  • Direct solid-phase synthesis comprises attachment of a C-terminal amino acid to a resin, and step-by step elongation of the peptide chain, with pre- activated amino acids.
  • This route is expensive because it requires large excesses of starting amino acids and additionally is quite labor consuming as the peptide size increases, necessitating complex purification procedures to separate the product from the impurities since they are very similar to the final product.
  • Liquid-phase synthesis comprises condensation of amino acids in solution.
  • Several blocks, containing from 2 to 5 amino acids may be synthesized independently, followed by condensation of these synthons to each other in the required sequence.
  • the advantage of this kind of processes is that it is less expensive than the previous one and the product is easier to purify. This method is also more effective for scale-up.
  • liquid phase synthesis of lengthy peptide blocks, for example having more than 3 amino acids is inefficient.
  • Liquid-phase octreotide synthesis has the drawback is that the method is extremely labor-intensive and time consuming.
  • U.S. Patent No. 6,346,601 describes a method for octreotide synthesis where a solid-phase method is used to obtain a 7-mer, followed by condensation in solution with the modified amino acid threoninol.
  • solid-phase synthesis to produce a 7-mer, only one less condensation is required compared to the solid-phase process for forming octreotide itself. Thus, only a marginal efficiency is introduced.
  • a process for obtaining octreotide or a pharmaceutically acceptable salt thereof by hybrid solid-phase - liquid-phase synthesis comprises the steps of condensing two or three peptide blocks using liquid phase condensation to form a condensation product followed by cyclizing the product.
  • Each peptide block contains two or more amino acid residues, and at least one of the blocks is synthesized by solid-phase synthesis.
  • the condensation product comprises in sequence the amino acids residues of octreotide.
  • the condensation product is cyclized to form a disulfide bridge between the two cysteine residues, thereby forming octreotide.
  • a process for obtaining an intermediate in octreotide synthesis by hybrid solid- phase - liquid-phase synthesis.
  • the synthesis of the intermediate comprises the steps of obtaining two or three peptide blocks, each peptide block containing two or more amino acid residues, and at least one of the blocks is synthesized by solid-phase synthesis. Subsequently, the peptide blocks are condensed using liquid phase condensation to form a condensation product, wherein the condensation product comprises in sequence the amino acids residues of octreotide.
  • This invention provides a more cost-effective and labor-saving method for obtaining OCT and its pharmaceutically acceptable salts by means of hybrid solid-phase - liquid-phase synthesis.
  • the invention involves liquid phase condensation of two peptide blocks, at least one of which is obtained by solid- phase synthesis, the blocks containing more two or more amino acid residue in every block, followed by formation of a disulfide bridge from the two cysteine groups.
  • three blocks may be condensed.
  • This hybrid solid phase-liquid phase method involves formation of one or more blocks of the octreotide amino acid sequence by solid-phase synthesis, followed by liquid phase condensation of the block(s) with required supplementary amino acids or other block(s) of amino acids.
  • This method is a blend of solid-phase and liquid-phase synthesis methods, combining the efficiencies of preparing shorter (6-mer or less) peptides using a solid-phase method with relative cheapness and easiness of purification of the product, characteristic of the liquid-phase method.
  • the methods of invention comprise synthesizing specific side- chain protected peptide fragment intermediates of OCT on a solid support or in solution, coupling of the protected fragments in solution to form a protected OCT, followed by deprotection of the side chains and oxidation to yield the final OCT.
  • the present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the OCT.
  • the invention provides a method for synthesis of octreotide, its salts, and intermediate compounds for preparation of octreotide.
  • Octreotide is been synthesized by condensation of two or three fragments in solution. At least one of these fragments is synthesized by solid phase synthesis, whereas the remaining one or two fragments could be synthesized by a liquid-phase or solid- phase method. Examples of such fragments are shown below.
  • At least one peptide block synthesized by solid-phase synthesis preferably contains at least three amino acid residues, and more preferably contains at least four amino acid residues.
  • Solid-phase synthesis may be performed on a super acid sensitive resin, such as CTC resin, or any other resin acceptable to those skilled in the art.
  • the step of condensing may be accomplished by use of HBTU, TBTU or HATU as a condensation agent, or by employing any other agent as would be acceptable to those skilled in the art.
  • An ⁇ -amino group on at least one peptide block may be protected with a Boc or Fmoc protecting group.
  • a side-chain of at least one amino acid residue of at least one peptide block may be protected with a t-
  • the preferred embodiment of the invention comprises the fragments synthesized by solid-phase method containing 3 or more amino acid residues.
  • two tetramers may be used.
  • the side-chains of the amino acid residues of peptide fragments may be protected with standard protecting groups such as t-Butyl, trityl, Boc, Acm.
  • the tBu group is preferred side-chain protecting group for amino acid residues Thr and threoninol;
  • the Trt and Acm groups are preferred side-chain protecting groups for Cys;
  • the Boc group is preferred side-chain protecting group for amino acid residues Lys and Trp.
  • Resin loading can be performed via reaction of excess of an amino acid or an amino alcohol and super acid sensitive resin (for example, 2-chIorotrityl chloride resin) in the presence of amine. Standard Fmoc protocols can be used for synthesis of the fragments.
  • Removal of the Fmoc protecting group from the terminal amine group can be accomplished by treating the resin with piperidine solution in DMF.
  • the protected amino acid may be activated through the reaction with condensing agents well- known to those skilled in the art (such as HBTU or TBTU). Coupling completion may be monitored with a qualitative ninhydrin test.
  • the peptide fragments synthesized via solid phase synthesis techniques can be cleaved by acidic treatment of the peptidyl-resin with dilute solution of acid.
  • the preferred acids for this purpose are TFA or HCI.
  • the cleaved peptide fragments can be coupled in the solution through activation of the N-terminal fragment carrying alpha-amino protecting group (Boc or Fmoc for example) with an appropriate coupling agent.
  • the preferred coupling agents are HBTU or TBTU, though other usually used agents might be chosen for this transformation.
  • the protected octapeptide can be precipitated by the addition of water and collected by vacuum filtration.
  • the final deprotection of the OCT can be done by treatment of the protected peptide with the solution of acid, and the preferred acid is TFA.
  • the cyclic product can be obtained by reacting the linear peptide with an appropriate reagent (for example hydrogen peroxide or iodine) in a buffer solution.
  • Crude product can be purified by using any acceptable methodology in the art, such as reverse phase, normal-phase or ion-exchange chromatography.
  • the 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS reactor and washed with 250 ml of DCM.
  • the bed was drained and a solution of Fmoc-Thr(tBu)-ol (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added.
  • the mixture was agitated with nitrogen bubbling for 2 hrs.
  • the bed was drained and washed with 250 ml of DCM.
  • the active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min.
  • the bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
  • Example 2 Fmoc-(D)-Trp(Boc)-CTC-resin synthesis
  • the 2-chlorotrityl chloride resin 25g, 1 eq
  • the bed was drained and a solution of
  • the mixture was agitated with nitrogen bubbling for 2 hrs.
  • the bed was drained and washed with 250 ml of DCM.
  • the active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min.
  • the bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
  • Fmoc protecting group from the terminal amine was accomplished by treating the resin with 2 aliquots of 20% solution piperidine in DMF. The resin is then washed 5-7 times with aliquots of DMF to remove the Fmoc by-products.
  • Fmoc-Cys(Trt)-OH was activated as follows. The Fmoc-protected amino acid (2 eq), 1-hydroxybenzotriazole hydrate (HOBT) (2 eq) and DIPEA (4 eq) were dissolved in NMP (about 10 volumes) at rt. The solution is chilled to 0-5°C and then HBTU (2 eq) is added followed by stirring for 5-15 min to dissolve.
  • the solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 15 g of the peptide fragment.
  • the peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM for about 2 min, followed by 200 ml of 0.5% TFA in DCM.
  • the cleavage fractions were collected onto pyridine (1 :1 ratio to TFA).
  • the cleavage washes were concentrated under vacuum to a volume 50 ml.
  • the product was precipitated with addition of 200 ml of water.
  • the slurry was stirred for 30 min.
  • the solids were collected by vacuum filtration and washed with 100 ml of water.
  • the product was air dried to give 17 g of the peptide fragment.
  • Example 5 Synthesis ofBoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)- Thr(tBu)-Cys(Trt)-Thr(tBu)-ol
  • a 25 ml round bottom flask containing a magnetic stir bar was charged with Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol, Boc-(D)-Phe-Cys(Trt)-Phe-(D)- Trp(Boc)-OH and HOBt.
  • Example 6 Synthesis of(D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol. Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)- Thr(tBu)-ol was cleaved with the mixture 95%TFA-2.5%EDT-2.5%H 2 0 at room temperature for 2 hours. The cleavage solution was filtered, the resin was washed with TFA. The combined washings were concentrated under vacuum to volume 0.5-1 ml followed by addition of 10 volumes of cold ether.
  • Example 7 Synthesis of Octreotide (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol was dissolved in water at concentration 100 mg/L. The pH of the solution was adjusted with 10 % NaOH to 8.0. 0.5 ml of H 2 0 2 was added to the solution. The reaction mixture was stirred for 2 hrs, lyophilized. The crude product was purified by reverse phase HPLC and ion-exchange LC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A hybrid solid phase-liquid phase method of octreotide synthesis is described, along with methods for preparation of intermediate compounds useful in the synthesis of Octreotide. The method comprises liquid phase condensation of two or three peptide blocks, of which at least one is synthesized by solid-phase method. Each block contains two or more amino acid residues. The method combines the time and labor effectiveness of the solid-phase method with relative cheapness and easiness of purification of the product, characteristic of the liquid-phase method.

Description

PROCESS FOR OCTREOTIDE SYNTHESIS
This application claims priority to and all benefit of Canadian Patent Application No. 2,458,084, filed March 12, 2004, the entirety of which is incorporated herein by reference. Background of the invention Octreotide (OCT) is the active pharmaceutical ingredient of the drug Sandostatin, using in treatment of some cancer diseases, especially acromegaly etc. It has the following chemical structure: (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol.
Conventional syntheses of OCT may be divided two main approaches, direct solid-phase synthesis and liquid-phase synthesis. Direct solid-phase synthesis comprises attachment of a C-terminal amino acid to a resin, and step-by step elongation of the peptide chain, with pre- activated amino acids. This route is expensive because it requires large excesses of starting amino acids and additionally is quite labor consuming as the peptide size increases, necessitating complex purification procedures to separate the product from the impurities since they are very similar to the final product. These shortcomings are especially important for large scale industrial production of the product. For example, see Canadian Patent Application 2,309,312 and U.S. Patent No. 6,476,186. With each successive condensation reaction required to add an amino acid, waste of starting materials increases, and purification steps are repeated. Liquid-phase synthesis comprises condensation of amino acids in solution. Several blocks, containing from 2 to 5 amino acids may be synthesized independently, followed by condensation of these synthons to each other in the required sequence. For example, see WO 03/097668; U.S. Patent No. 4,395,403; and RU 2196144 C1. The advantage of this kind of processes is that it is less expensive than the previous one and the product is easier to purify. This method is also more effective for scale-up. However, liquid phase synthesis of lengthy peptide blocks, for example having more than 3 amino acids, is inefficient. Liquid-phase octreotide synthesis has the drawback is that the method is extremely labor-intensive and time consuming. U.S. Patent No. 6,346,601 describes a method for octreotide synthesis where a solid-phase method is used to obtain a 7-mer, followed by condensation in solution with the modified amino acid threoninol. However, by using solid- phase synthesis to produce a 7-mer, only one less condensation is required compared to the solid-phase process for forming octreotide itself. Thus, only a marginal efficiency is introduced. Summary of the invention According to an embodiment of the invention, there is provided a process for obtaining octreotide or a pharmaceutically acceptable salt thereof by hybrid solid-phase - liquid-phase synthesis. The synthesis comprises the steps of condensing two or three peptide blocks using liquid phase condensation to form a condensation product followed by cyclizing the product. Each peptide block contains two or more amino acid residues, and at least one of the blocks is synthesized by solid-phase synthesis. The condensation product comprises in sequence the amino acids residues of octreotide. In the step of cyclizing, the condensation product is cyclized to form a disulfide bridge between the two cysteine residues, thereby forming octreotide. Further, according to another embodiment of the invention, a process is provided for obtaining an intermediate in octreotide synthesis by hybrid solid- phase - liquid-phase synthesis. The synthesis of the intermediate comprises the steps of obtaining two or three peptide blocks, each peptide block containing two or more amino acid residues, and at least one of the blocks is synthesized by solid-phase synthesis. Subsequently, the peptide blocks are condensed using liquid phase condensation to form a condensation product, wherein the condensation product comprises in sequence the amino acids residues of octreotide. This invention provides a more cost-effective and labor-saving method for obtaining OCT and its pharmaceutically acceptable salts by means of hybrid solid-phase - liquid-phase synthesis. The invention involves liquid phase condensation of two peptide blocks, at least one of which is obtained by solid- phase synthesis, the blocks containing more two or more amino acid residue in every block, followed by formation of a disulfide bridge from the two cysteine groups. Optionally, three blocks may be condensed. This hybrid solid phase-liquid phase method involves formation of one or more blocks of the octreotide amino acid sequence by solid-phase synthesis, followed by liquid phase condensation of the block(s) with required supplementary amino acids or other block(s) of amino acids. This method is a blend of solid-phase and liquid-phase synthesis methods, combining the efficiencies of preparing shorter (6-mer or less) peptides using a solid-phase method with relative cheapness and easiness of purification of the product, characteristic of the liquid-phase method. Generally, the methods of invention comprise synthesizing specific side- chain protected peptide fragment intermediates of OCT on a solid support or in solution, coupling of the protected fragments in solution to form a protected OCT, followed by deprotection of the side chains and oxidation to yield the final OCT. The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the OCT. Detailed description of the invention The invention provides a method for synthesis of octreotide, its salts, and intermediate compounds for preparation of octreotide. Octreotide is been synthesized by condensation of two or three fragments in solution. At least one of these fragments is synthesized by solid phase synthesis, whereas the remaining one or two fragments could be synthesized by a liquid-phase or solid- phase method. Examples of such fragments are shown below. Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (ll) NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (lll) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V) NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI)
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX)
Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X)
Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI)
NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII) Optimally, two peptide blocks are condensed in the step of condensing.
At least one peptide block synthesized by solid-phase synthesis preferably contains at least three amino acid residues, and more preferably contains at least four amino acid residues. Solid-phase synthesis may be performed on a super acid sensitive resin, such as CTC resin, or any other resin acceptable to those skilled in the art. The step of condensing may be accomplished by use of HBTU, TBTU or HATU as a condensation agent, or by employing any other agent as would be acceptable to those skilled in the art. An α-amino group on at least one peptide block may be protected with a Boc or Fmoc protecting group. Further, a side-chain of at least one amino acid residue of at least one peptide block may be protected with a t-
Butyl, Trityl, Boc, or Acm protecting group. Solid-phase synthesis of short fragments containing 2 amino acid residues is economically not expedient, therefore the preferred embodiment of the invention comprises the fragments synthesized by solid-phase method containing 3 or more amino acid residues. For example, two tetramers may be used. The side-chains of the amino acid residues of peptide fragments may be protected with standard protecting groups such as t-Butyl, trityl, Boc, Acm. The tBu group is preferred side-chain protecting group for amino acid residues Thr and threoninol; the Trt and Acm groups are preferred side-chain protecting groups for Cys; the Boc group is preferred side-chain protecting group for amino acid residues Lys and Trp. Resin loading can be performed via reaction of excess of an amino acid or an amino alcohol and super acid sensitive resin (for example, 2-chIorotrityl chloride resin) in the presence of amine. Standard Fmoc protocols can be used for synthesis of the fragments.
Removal of the Fmoc protecting group from the terminal amine group can be accomplished by treating the resin with piperidine solution in DMF. The protected amino acid may be activated through the reaction with condensing agents well- known to those skilled in the art (such as HBTU or TBTU). Coupling completion may be monitored with a qualitative ninhydrin test. The peptide fragments synthesized via solid phase synthesis techniques can be cleaved by acidic treatment of the peptidyl-resin with dilute solution of acid. The preferred acids for this purpose are TFA or HCI. The cleaved peptide fragments can be coupled in the solution through activation of the N-terminal fragment carrying alpha-amino protecting group (Boc or Fmoc for example) with an appropriate coupling agent. The preferred coupling agents are HBTU or TBTU, though other usually used agents might be chosen for this transformation. The protected octapeptide can be precipitated by the addition of water and collected by vacuum filtration. The final deprotection of the OCT can be done by treatment of the protected peptide with the solution of acid, and the preferred acid is TFA. The cyclic product can be obtained by reacting the linear peptide with an appropriate reagent (for example hydrogen peroxide or iodine) in a buffer solution. Crude product can be purified by using any acceptable methodology in the art, such as reverse phase, normal-phase or ion-exchange chromatography. Examples Example 1: Fmoc-Thr(tBu)-ol-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS reactor and washed with 250 ml of DCM. The bed was drained and a solution of Fmoc-Thr(tBu)-ol (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added. The mixture was agitated with nitrogen bubbling for 2 hrs. The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
Example 2: Fmoc-(D)-Trp(Boc)-CTC-resin synthesis The 2-chlorotrityl chloride resin (25g, 1 eq) was charged to a 500 ml SPS reactor and washed with 250 ml of DCM. The bed was drained and a solution of
Fmoc-(D)Trp(Boc)-OH (1.5 eq) and DIPEA (3 eq) in 250 ml of DCM was added.
The mixture was agitated with nitrogen bubbling for 2 hrs. The bed was drained and washed with 250 ml of DCM. The active sites on the resin were end-capped with 200 ml of a 5:4:1 MeOH:DCM:DIPEA solution for 20 min. The bed was drained, washed with 4x250 ml of DCM, dried with an argon purge to give 34.4 g of loaded resin.
Example 3: Solid phase synthesis of the peptide fragment Lys(Boc)-
Thr(tBu)-Cys(Trt)-Thr(tBu)-ol The 500 ml SPS reactor was charged 20.0 g of Fmoc-Thr(tBu)-ol-2- chlorotrityl resin. The resin was conditioned in 200ml of DCM with nitrogen agitation for about 15 min to swell the beads, and then drained. Removal of the
Fmoc protecting group from the terminal amine was accomplished by treating the resin with 2 aliquots of 20% solution piperidine in DMF. The resin is then washed 5-7 times with aliquots of DMF to remove the Fmoc by-products. Fmoc-Cys(Trt)-OH was activated as follows. The Fmoc-protected amino acid (2 eq), 1-hydroxybenzotriazole hydrate (HOBT) (2 eq) and DIPEA (4 eq) were dissolved in NMP (about 10 volumes) at rt. The solution is chilled to 0-5°C and then HBTU (2 eq) is added followed by stirring for 5-15 min to dissolve. The solution of activated amino acid was added to the drained resin and the reaction was agitated with argon bubbling for about 1 hr. Coupling completion may be monitored with a qualitative ninhydrin test. The cycle was repeated for Fmoc-Thr(tBu)-OH and Fmoc-Lys(Boc)-OH.
Following the final coupling reaction and washings the deprotection step was performed and the resin was washed with DMA, DCM. The resin was dried with an argon purge to give 36 g resin-bond peptide. The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in
DCM for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine (1 :1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min.
The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 15 g of the peptide fragment.
Example 4: Solid phase synthesis of the peptide fragment Boc-(D)-Phe-
Cys(Trt)-Rhe-(D)-Trp(Boc)-OH The 500 ml SPS reactor was charged with 20.0 g of Fmoc-(D)-Trp(Boc)-2- chlorotrityl resin. The resin was conditioned in 200ml of DCM with nitrogen agitation for about 15 min to swell the beads, and then drained. After Fmoc removal, Fmoc-Phe-OH was activated as described above. The cycle was repeated for Fmoc-Cys(Trt)-OH and Boc-(D)-Phe-OH. Following the final coupling reaction and washings the resin was dried with an argon purge to give 38 g resin-bond peptide. The peptide was cleaved from 21 g of the resin using 300 ml of 1 % TFA in DCM for about 2 min, followed by 200 ml of 0.5% TFA in DCM. The cleavage fractions were collected onto pyridine (1 :1 ratio to TFA). The cleavage washes were concentrated under vacuum to a volume 50 ml. The product was precipitated with addition of 200 ml of water. The slurry was stirred for 30 min. The solids were collected by vacuum filtration and washed with 100 ml of water. The product was air dried to give 17 g of the peptide fragment. Example 5: Synthesis ofBoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)- Thr(tBu)-Cys(Trt)-Thr(tBu)-ol A 25 ml round bottom flask containing a magnetic stir bar was charged with Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol, Boc-(D)-Phe-Cys(Trt)-Phe-(D)- Trp(Boc)-OH and HOBt. The solids were dissolved in 9:1 DMA:DMSO (5 ml) containing DIPEA, and then cooled to 0-5°C under nitrogen. To the cool solution HBTU was added. The reaction mixture was stirred for 15 min, then warmed up to room temperature and stirred an additional 60 min. The peptide was precipitated from the solution by addition of water, 7 ml. The solid was collected by filtration, washed with water and dried give 0.30 g of Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol. Example 6: Synthesis of(D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol. Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)- Thr(tBu)-ol was cleaved with the mixture 95%TFA-2.5%EDT-2.5%H20 at room temperature for 2 hours. The cleavage solution was filtered, the resin was washed with TFA. The combined washings were concentrated under vacuum to volume 0.5-1 ml followed by addition of 10 volumes of cold ether. The pellets were collected by centrifugation and washed with cold ether. The product was extracted with 50% ACN and dried by lyophilization. Example 7: Synthesis of Octreotide (D)-Phe-Cys-Phe-(D)-Trp-Lys-Thr-Cys-Thr-ol was dissolved in water at concentration 100 mg/L. The pH of the solution was adjusted with 10 % NaOH to 8.0. 0.5 ml of H202 was added to the solution. The reaction mixture was stirred for 2 hrs, lyophilized. The crude product was purified by reverse phase HPLC and ion-exchange LC.

Claims

Claims
1. A process for obtaining octreotide or a pharmaceutically acceptable salt thereof by hybrid solid-phase - liquid-phase synthesis, comprising the steps of: condensing two or three peptide blocks using liquid phase condensation to form a condensation product, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis, and wherein the condensation product comprises in sequence the amino acids residues of octreotide; and cyclizing the condensation product to form a disulfide bridge between two cysteine residues.
2. The process of claim 1 wherein two peptide blocks are condensed in the step of condensing.
3. The process of claim 1 or 2, wherein one peptide block synthesized by solid-phase synthesis contains at least three amino acid residues.
4. The process of claim 3, wherein one peptide block synthesized by solid- phase synthesis contains at least four amino acid residues.
5. The process of any one of claims 1 to 4, wherein solid phase synthesis is performed on super acid sensitive resin.
6. The process of claim 5, wherein the super acid sensitive resin is CTC resin.
7. The process of any one of claims 1 to 6, wherein the step of condensing is accomplished by use of HBTU, TBTU or HATU as a condensation agent.
8. The process of any one of claims 1 to 7, wherein an α-amino group on at least one peptide block is protected with a Boc or Fmoc protecting group.
9. The process of any one of claims 1 to 8, wherein a side-chain of at least one amino acid residue of at least one peptide block is protected with a t-Butyl,
Trityl, Boc, or Acm protecting group.
10. The process of any one of claims 1 to 19, wherein the step of cyclizing is accomplished by action of an oxidative reagent.
1 1. The process of claim 10, wherein the oxidative reagent is hydrogen peroxide or iodine.
12. The process of any one of claims 1 to 11 , wherein at least one of the peptide blocks is selected from the group consisting of:
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (l)
Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (ll)
NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (lll)
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V)
NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI)
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII)
Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII)
NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X)
Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and
NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
13. The process of any one of claims 1 to 11 wherein the step of condensing comprises condensing two peptide blocks formed using solid phase synthesis, the peptide blocks having the following amino acid residues: (D)-Phe-Cys-Phe-(D)-Trp and Lys-Thr-Cys-Thr-ol.
14. The process of claim 12 wherein the two peptide blocks are: Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (l) and
NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (lll).
15. The process of claim 14 wherein the peptide block Fmoc-(D)-Phe- Cys(Trt)-Phe-(D)-Trp(Boc)-OH (I) is prepared by forming a protected resin: Fmoc-(D)-Trp(Boc)-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin to form Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-CTC- resin; and cleaving the peptide block from the resin.
16. The process of claim 14 wherein the peptide block NH2-Lys(Boc)- Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (III) is prepared by forming a protected resin: Fmoc-Thr(tBu)-ol-CTC-resin; deprotecting the resin; successively coupling amino acids to the resin; and cleaving the peptide block from the resin.
17. The process of claim 2 wherein the two peptide blocks are prepared using
Figure imgf000012_0001
18. A process for obtaining an intermediate in octreotide synthesis by hybrid solid-phase - liquid-phase synthesis, comprising the steps of: obtaining two or three peptide blocks, each peptide block containing two or more amino acid residues, at least one of the blocks being synthesized by solid-phase synthesis; condensing the peptide blocks using liquid phase condensation to form a condensation product, wherein the condensation product comprises in sequence the amino acids residues of octreotide.
19. The process of claim 18 wherein two peptide blocks are condensed in the step of condensing.
20. The process of claim 18 or 19, wherein one peptide block synthesized by solid-phase synthesis contains at least three amino acid residues.
21. The process of claim 20, wherein one peptide block synthesized by solid- phase synthesis contains at least four amino acid residues.
22. The process of any one of claims 18 to 21 , wherein solid phase synthesis is performed on super acid sensitive resin.
23. The process of claim 22, wherein the super acid sensitive resin is CTC resin.
24. The process of any one of claims 18 to 23, wherein the step of condensing is accomplished by use of HBTU, TBTU or HATU as a condensation agent.
25. The process of any one of claims 18 to 24, wherein an α-amino group on at least one peptide block is protected with a Boc or Fmoc protecting group.
26. The process of any one of claims 18 to 25, wherein a side-chain of at least one amino acid residue of at least one peptide block is protected with a t- Butyl, Trityl, Boc, or Acm protecting group.
27. The process of any one of claims 18 to 26, wherein at least one of the peptide blocks is selected from the group consisting of:
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (l)
Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-OH (ll)
NH2-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (lll)
Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (IV) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-OH (V)
NH2-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (VI) Fmoc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VII) Boc-(D)-Phe-Cys(Trt)-Phe-(D)-Trp(Boc)-Lys(Boc)-Thr(tBu)-OH (VIII) NH2-Cys(Trt)-Thr(tBu)-ol (IX) Fmoc-(D)-Phe-Cys(Trt)-Phe-OH (X) Boc-(D)-Phe-Cys(Trt)-Phe-OH (XI) and NH2-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Trt)-Thr(tBu)-ol (XII).
PCT/CA2005/000378 2004-03-12 2005-03-14 Process for octreotide synthesis WO2005087794A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,458,084 2004-03-12
CA002458084A CA2458084A1 (en) 2004-03-12 2004-03-12 Novel process for octreotide synthesis

Publications (1)

Publication Number Publication Date
WO2005087794A1 true WO2005087794A1 (en) 2005-09-22

Family

ID=34975525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2005/000378 WO2005087794A1 (en) 2004-03-12 2005-03-14 Process for octreotide synthesis

Country Status (2)

Country Link
CA (1) CA2458084A1 (en)
WO (1) WO2005087794A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089757A2 (en) 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
RU2435780C1 (en) * 2010-07-08 2011-12-10 Закрытое Акционерное Общество "Фарм-Синтез" Method for producing cyclic peptide-octreotide
CN102850438A (en) * 2012-09-19 2013-01-02 上海昂博生物技术有限公司 Solid phase preparation method of crude octrotide
WO2013046233A2 (en) 2011-09-30 2013-04-04 Mylan Laboratories Ltd Process for the preparation of octreotide acetate
WO2013132505A1 (en) 2012-03-09 2013-09-12 Natco Pharma Limited Improved process for preparation of octreotide by solution phase peptide synthesis
JP2014162722A (en) * 2013-02-21 2014-09-08 Chemical And Biopharmaceutical Labolatories Of Patra Sa Solid-phase peptide synthesis via side chain bond
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
WO2017175107A1 (en) * 2016-04-04 2017-10-12 Emcure Pharmaceuticals Limited Process for preparation of octreotide acetate
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10183966B2 (en) 2013-02-21 2019-01-22 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
CN117534728A (en) * 2024-01-10 2024-02-09 哈尔滨吉象隆生物技术有限公司 Preparation method of octreotide trisulfide bond impurity E

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346601B1 (en) * 1998-01-29 2002-02-12 Lipotec S.A. Procedure for obtaining the somatostatin analog, octreotide
US6476186B1 (en) * 2000-05-23 2002-11-05 Institute Of Nuclear Energy Research Process for preparing octreotide and derivatives thereof
WO2003097668A2 (en) * 2002-05-22 2003-11-27 Chaturvedi Nishith C Novel process for production of the somatostatin analog, octreotide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346601B1 (en) * 1998-01-29 2002-02-12 Lipotec S.A. Procedure for obtaining the somatostatin analog, octreotide
US6476186B1 (en) * 2000-05-23 2002-11-05 Institute Of Nuclear Energy Research Process for preparing octreotide and derivatives thereof
WO2003097668A2 (en) * 2002-05-22 2003-11-27 Chaturvedi Nishith C Novel process for production of the somatostatin analog, octreotide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUCKDORFER T. ET AL: "From production peptides in milligram amounts for research to multi-tons quantities for drug of the future.", CURRENT PHARMACEUTICAL BIOTECHNOLOGY., vol. 5, no. 1, February 2004 (2004-02-01), pages 29 - 43 *
FISCHER P.M. ET AL: "Liquid-phase peptide synthesis on polyethylene glycol(PEG) supports using strategies based on the 9-fluorenylmethoxycarbonyl amino protecting group: applications of pegylated peptides in biochemical assays.", JOURNAL OF PEPTIDE SCIENCE., vol. 8, no. 9, August 2002 (2002-08-01), pages 529 - 542, XP055045027, DOI: doi:10.1002/psc.413 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010089757A2 (en) 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US8377891B2 (en) 2008-11-07 2013-02-19 Usv, Ltd. Process for synthesis of cyclic octapeptide
US9801931B2 (en) 2009-01-23 2017-10-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
RU2435780C1 (en) * 2010-07-08 2011-12-10 Закрытое Акционерное Общество "Фарм-Синтез" Method for producing cyclic peptide-octreotide
WO2013046233A2 (en) 2011-09-30 2013-04-04 Mylan Laboratories Ltd Process for the preparation of octreotide acetate
WO2013046233A3 (en) * 2011-09-30 2013-06-13 Mylan Laboratories Ltd Process for the preparation of octreotide acetate
WO2013132505A1 (en) 2012-03-09 2013-09-12 Natco Pharma Limited Improved process for preparation of octreotide by solution phase peptide synthesis
CN102850438B (en) * 2012-09-19 2014-11-05 上海昂博生物技术有限公司 Solid phase preparation method of crude octrotide
CN102850438A (en) * 2012-09-19 2013-01-02 上海昂博生物技术有限公司 Solid phase preparation method of crude octrotide
JP2014162722A (en) * 2013-02-21 2014-09-08 Chemical And Biopharmaceutical Labolatories Of Patra Sa Solid-phase peptide synthesis via side chain bond
US10183966B2 (en) 2013-02-21 2019-01-22 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2017175107A1 (en) * 2016-04-04 2017-10-12 Emcure Pharmaceuticals Limited Process for preparation of octreotide acetate
CN117534728A (en) * 2024-01-10 2024-02-09 哈尔滨吉象隆生物技术有限公司 Preparation method of octreotide trisulfide bond impurity E

Also Published As

Publication number Publication date
CA2458084A1 (en) 2005-09-12

Similar Documents

Publication Publication Date Title
JP4405594B2 (en) Improved solid phase peptide synthesis and reagents for use in such synthesis
CN107406480B (en) Peptide synthesis method
EP3708576B1 (en) Method for preparing amg 416
JP5199126B2 (en) Synthesis of glucagon-like peptides
KR101904808B1 (en) Process for the manufacture of degarelix and its intermediates
HUP0101629A2 (en) Process for the preparation of resin-bound cyclic peptides
WO2009003666A1 (en) Process for the production of pramlintide
US8377891B2 (en) Process for synthesis of cyclic octapeptide
AU2014282839B2 (en) Peptide-resin conjugate and use thereof
WO2005087794A1 (en) Process for octreotide synthesis
US7176282B1 (en) Solid-phase peptide synthesis and agent for use in such synthesis
CN114805480A (en) Preparation method of octreotide
Cavallaro et al. Solid‐phase synthesis of a dendritic peptide related to a retinoblastoma protein fragment utilizing a combined boc‐and fmoc‐chemistry approach
CN114057829A (en) Solid-phase synthesis method of N-methylated polypeptide
CN115433266A (en) Solid-phase synthesis method of teriparatide
CN119684391A (en) A method for synthesizing a polypeptide containing a flexible linker
HK40036914A (en) Method for preparing amg 416
HK1217022B (en) Peptide-resin conjugate and use thereof
EP2343309A1 (en) Method for producing a peptide
JPH0525196A (en) Method for synthesizing cyclic peptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase